Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics (NTLA) PT Lowered to $29 at Citi

May 9, 2024 4:40 PM EDT

Citi analyst David Lebowitz lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $29.00 (from $31.00) while maintaining a Neutral rating.

The analyst comments "On the 1Q24 call, Intellia announced a new NTLA-2001 Ph3 trial in ATTR-PN (starting 2024). NTLA-2001s Ph3 MAGNITUDE... More